Back to search

Peptide record

TPDB91910

Bombinin H-BO Antibacterial Anticancer Antifungal Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91910
Bombinin H-BO
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0 dbACP CAFPdb dbAMP ToxinPred 3.0
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
IIGPVLGLIGKALGGLL-NH2
Physicochemical Analysis
C77H138N18O18
RNDCEQHMFSTWY
GL
1604.05
10.10
1
0
10
+1
-2.34
1.824
206.47
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
0
0.00
0
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
5
G
0
H
3
I
5
L
1
K
0
M
0
F
1
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 5 H: 0 I: 3 L: 5 K: 1 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
17
C77H138N18O18
1604.05
10.10
+1
-2.34
1.824
Amidation
L
Linear
Free
Antimicrobial
Bombina orientalis
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.99 µM
Anticancer
0.99 µM

Target

Liver Cancer
SK-HEP-1
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.88 µM
Anticancer
2.88 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 3.87 µM
Anticancer
3.87 µM

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

Cell Viability
Cell Viability ~ 40% at 2.5 µM
Anticancer
~40 % at 2.5 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

Cell Viability
Cell Viability ~ 20% at 5 µM
Anticancer
~20 % at 5 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

Cell Viability
Cell Viability < 20% at 5 µM
Anticancer
<20 % at 5 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018